Abel Hall LLC’s GSK GSK Stock Holding History

Abel Hall LLC’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$484K	Sell	10,045 -3,994	-28%	-$204K	0.09%	235
2026 Q2	$736K	Sell	14,039 -777	-5%	-$41.1K	0.13%	135
2026 Q1	$818K	Sell	14,816 -8,876	-37%	-$481K	0.17%	95
2025 Q4	$1.16M	Buy	23,692 +9,359	+65%	+$437K	0.27%	50
2025 Q3	$619K	Sell	14,333 -497	-3%	-$19.4K	0.25%	63
2025 Q2	$569K	Buy	14,830 +294	+2%	+$11.2K	0.26%	64
2025 Q1	$563K	Buy	14,536 +1,763	+14%	+$64.5K	0.34%	46
2024 Q4	$432K	Sell	12,773 -672	-5%	-$24.2K	0.28%	59
2024 Q3	$550K	Buy	13,445 +126	+0.9%	+$5.16K	0.36%	41
2024 Q2	$513K	Buy	13,319 +163	+1%	+$6.86K	0.36%	41
2024 Q1	$564K	Buy	13,156 +107	+0.8%	+$4.41K	0.42%	36
2023 Q4	$484K	Buy	+13,049	New	+$468K	0.41%	41

Other funds holding GSK

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return

Equity Investment Corp Atlanta, Georgia $5.3B AUM 8.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Letko, Brosseau & Associates Montreal, Quebec, Canada $6.9B AUM 29.83% 1-Year Est. Return

Miller Howard Investments Kingston, New York $3.72B AUM 18.2% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Abel Hall LLC's GSK Position: Q3 2026 in Review

Abel Hall LLC reduced its GSK (GSK) stake by 28% in Q3 2026, selling an estimated $204K and leaving 10,045 shares worth $484K. The position accounts for 0.09% of the portfolio, ranked #235.

Abel Hall LLC first reported a position in GSK in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.16M in Q4 2025. 543 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

Abel Hall LLC held 10,045 shares of GSK worth $484K as of Q3 2026.
Abel Hall LLC sold 3,994 GSK shares in Q3 2026, an estimated $204K.
GSK made up 0.09% of Abel Hall LLC's portfolio in Q3 2026, its #235 holding.
Abel Hall LLC first reported a position in GSK in Q4 2023 and has held it in 12 quarters since.
Abel Hall LLC's GSK position peaked at $1.16M in Q4 2025.
543 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.